BioSpace News Archive

Tricentis, a leader in test automation for modern cloud and enterprise applications, announced today the acquisition of Tx3 Services, a provider of automated quality and compliance software testing solutions for life sciences companies.

Nora Pharma has acquired the assets of Pharmapar, a Quebec -based company that has been distributing generic drugs for over 20 years.

The Foundation for the National Institutes of Health announced the appointment of Dr. Julie Louise Gerberding, the 15th Director of the Centers for Disease Control and Prevention and an executive at Merck & Co., Inc., as its next Chief Executive Officer.

The pioneer and leader of bioelectronic medicine achieved multiple milestones throughout 2021, securing CMS HCPCS codes, IETF clinical guidelines, provider network contracts, and commercial reimbursement from leading national and regional health plans

Adults hospitalized for acute heart failure were 36% more likely to experience a clinical benefit over 90 days if initiated on Jardiance® (empagliflozin) following stabilization and prior to discharge compared with placebo in the phase III EMPULSE trial, Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced today.

PharmaJet® announced that their poster will be presented on March 1-3, 2022 at the Vaccination Acceptance Research Network conference, sponsored by the Sabin Vaccine Institute.

Orange County, California based MediPines Corporation has announced the addition of Gary C. Sieck, PhD; George M. Zlupko, MD, FCCP; and Aidan Raney, MD, FACC to its medical and scientific advisory board.

Synergy Biomedical, LLC, a developer of innovative biomaterial products, today announced the launching of BIOSPHERE® MIS II, Next Generation Minimally Invasive Bone Graft Delivery System. Synergy continues to add solutions for surgeons with new innovative biomaterial products to an already successful portfolio.

Pieris Pharmaceuticals, Inc. today reported financial results for the fiscal year ended December 31, 2021 and provided an update on the Company’s recent and anticipated future developments.

PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided corporate highlights.